Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 41Other hematologic neoplasm 14Plasma cell 5Gastrointestinal 3CNS 3Other solid neoplasm 2Gynecologic 2Breast 2Thoracic 1Sarcoma 1Head & Neck 1

Conditions

Platinum-Resistant Ovarian Carcinoma 1Ovarian Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 140pembrolizumab 119Carboplatin 104Bevacizumab 90Cisplatin 67Specimen Handling 62Magnetic Resonance Spectroscopy 51olaparib 50Gemcitabine 39Nivolumab 36Biopsy 36liposomal doxorubicin 32Taxes 31Cyclophosphamide 31Blood Specimen Collection 29niraparib 27lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 22fludarabine 21atezolizumab 21Radiotherapy 21Brachytherapy 21Disulfides 20durvalumab 19Surveys and Questionnaires 19dostarlimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunotherapy, Adoptive × Gynecologic × 1 year × Clear all
NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
4 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05225363 2025-07-01

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

City of Hope Medical Center

Phase 1 Recruiting
33 enrolled
Gynecologic

Platinum-Resistant Ovarian Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡